PMA device
HeartLight Catheter, HeartLight X3 Console V2
Cardiofocus, Inc. · Catheter, Percutaneous, Cardiac Ablation, For Treatment Of Atrial Fibrillation (OAE, Class III) · First FDA decision Apr 1, 2016, newest Aug 11, 2023Atrial fibrillation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
12
Naming "HeartLight"
MAUDE reports
211
Brand "HeartLight", since 2015
PubMed studies
7
Mentioning "HeartLight"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing HeartLight Catheter, HeartLight X3 Console V2
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- HeartLight Catheter, HeartLight X3 Console V2PMA supplement
P150026-S015 · Decided Aug 11, 2023 · 162 days after receipt · Normal 180 Day Track No User Fee
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
- HeartLight Catheter, HeartLight X3 Console V2PMA supplement
P150026-S014 · Decided Feb 24, 2023 · 308 days after receipt · Normal 180 Day Track
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
- HeartLight Catheter and HeartLight ConsolePMA supplement
P150026-S011 · Decided Jul 1, 2020 · 30 days after receipt · Normal 180 Day Track No User Fee
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Left Atrial Appendage Closure (LAAC)National determinationOn the books20.34Updated Nov 4, 2026
- Percutaneous Left Atrial Appendage (LAA) Closure TherapyNational analysisReview closedCAG-00445NUpdated Sep 21, 2026
- Cardiac Catheterization Performed In Other Than A Hospital SettingNational analysisReview closedCAG-00166NUpdated Sep 16, 2026
- Cardiac Catheterization Performed in Other than a Hospital Setting - RETIREDNational determinationOn the books20.25Updated Dec 3, 2024
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33959CGS Administrators, LLCUpdated Oct 30, 2026
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33557Wellpoint FederalUpdated Jul 14, 2026
- Percutaneous minimally invasive fusion/stabilization of the sacroiliac joint for the treatment of back painLocal determinationIn effectL36000WPS Insurance CorporationUpdated May 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "HeartLight", any status and sponsor, newest update first.
CardioFocusNot on our public-company list
NCT03168659 · 250 participants (planned) · Start Jun 16, 2017 · Primary completion Oct 2026
Device: HeartLight · For: Atrial Fibrillation
Sites: Tucson, Arizona; Chicago, Illinois; New York, New York · 4 sites in all
- CardioFocus vs. Contact Force Guided Pulmonary Vein Isolation in Paroxysmal Atrial FibrillationPivotal-lookingCompleted
I-Med-Pro GmbHAcademic, hospital or other
NCT03056222 · 360 participants · Start Apr 10, 2017 · Primary completion Aug 16, 2021
Device: Ablation catheter · For: Paroxysmal Atrial Fibrillation
Sites: Aalst, Belgium; Hasselt, Belgium; Prague, Czechia · 11 sites in all
CardioFocusNot on our public-company list
NCT03988244 · 11 participants · Start Feb 26, 2019 · Primary completion Apr 30, 2019
Device: HeartLight X3 · For: Atrial Fibrillation
Sites: Prague, Czechia
9 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "HeartLight", and for the whole product code for context.
This brand
211 reports: 16 malfunction, 193 injury, 2 death
Whole product code OAE
11,261 reports: 5,551 malfunction, 5,370 injury, 334 death
Newest reports for this brand
- HEARTLIGHTInjury
1225698-2025-00002 · Received Mar 6, 2025 · Event dated Feb 11, 2025
Device type: Catheter, Percutaneous, Cardiac Ablation, For Treatment Of Atrial Fibrillation (OAE)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Nerve Damage
- HEARTLIGHTMalfunction
1225698-2025-00001 · Received Jan 31, 2025 · Event dated Jan 14, 2025
Device type: Catheter, Percutaneous, Cardiac Ablation, For Treatment Of Atrial Fibrillation (OAE)
Device problem as coded: Tear, Rip or Hole in Device Packaging
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- HEARTLIGHTInjury
1225698-2024-00018 · Received Dec 23, 2024 · Event dated Apr 11, 2018
Device type: Catheter, Percutaneous, Cardiac Ablation, For Treatment Of Atrial Fibrillation (OAE)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Nerve Damage
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1307-2025 · Started Feb 7, 2025 · Posted by FDA Mar 10, 2025
Reason given: Damage to the sterile barrier pouch of catheter, which could potentially compromise its sterility.
Cause as FDA categorized it: Process control · Device type: Catheter, Percutaneous, Cardiac Ablation, For Treatment Of Atrial Fibrillation (OAE)
Published research
The most relevant PubMed records for "HeartLight"[tiab]. The summary above synthesizes these.
- Initial multicenter clinical experience with the first-generation endoscopic guided laser balloon in Japan.
Goya M, Hirao K, Aonuma K, et al. · J Interv Card Electrophysiol · 2023Multicenter Study
- Pulmonary Vein Isolation Using the Visually Guided Laser Balloon: A Prospective, Multicenter, and Randomized Comparison to Standard Radiofrequency Ablation.
Dukkipati SR, Cuoco F, Kutinsky I, et al. · J Am Coll Cardiol · 2015Comparative Study, Multicenter Study
- Pulmonary vein isolation with a novel endoscopic ablation system using laser energy.
Schade A, Krug J, Szöllösi AG, et al. · Expert Rev Cardiovasc Ther · 2012Review
- HEartLight guided - PUre Pulmonary Vein Isolation Regardless of Concomitant Atrial Substrate: HEURECA Study.
Nagase T, Bordignon S, Perrotta L, et al. · Pacing Clin Electrophysiol · 2019Observational Study, Research Support, Non-U.S. Gov't
- Laser balloon ablation for AF: A systematic review and meta-analysis.
Reynolds MR, Zheng Q, Doros G · J Cardiovasc Electrophysiol · 2018Meta-Analysis, Systematic Review
- Balloon Devices for Atrial Fibrillation Therapy.
Metzner A, Wissner E, Lin T, et al. · Arrhythm Electrophysiol Rev · 2015
- Heartlight: reaching out to grieving children--in two languages.
Stevens K · Disch Plann Update · 1995
Other devices of this type
Also filed under product code OAE.
- Arctic Front Advance and Arctic Front Advance ProMedtronic Cryocath, LP · PMA 2024
- Arctic Front Cardiac Cryoablation Catheter SystemMedtronic Cryocath, LP · PMA 2024
- TactiCath Contact Force Ablation Catheter, Sensor EnabledSt Jude Medical · PMA 2023
- TactiFlex Sensor Enabled Ablation CatheterAbbott Medical · PMA 2026
- DiamondTemp Ablation SystemMedtronic, Inc. · PMA 2025
- TactiCath Quartz Contact Force Ablation CatheterSt Jude Medical · PMA 2021
- QDOT MICRO SystemBiosense Webster, Inc. · PMA 2025
- POLARx/POLARx FIT Cryoablation CathetersBoston Scientific Corporation · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.